Summary
A possible interaction between the calcium antagonist nimodipine and the H2-receptor antagonists cimetidine and ranitidine has been investigated in two separate studies in healthy subjects.
In eight young volunteers the concomitant administration of nimodipine 30 mg t.i.d. and cimetidine 1000 mg/d for 7 days led to a significant increase of the relative bioavailability of nimodipine. The changes in the pharmacokinetic parameters were not accompanied by discernible haemodynamic effects or any change in the tolerability of nimodipine.
There was no evidence of any significant change in the steady-state pharmacokinetics of nimodipine during five days of combined treatment with 30 mg t.i.d. nimodipine and ranitidine 300 mg/d given as single morning dose to twelve healthy, elderly subjects. Analysis of haemodynamics, clinical chemistry and tolerance also did not reveal any difference between the two treatment periods.
Similar content being viewed by others
References
Langley MS, Sorkin EM (1989) Nimodipine — a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 37: 669–699
Brandt L, Andersson KE, Ljunggren B, Saeveland H, Ryman T (1988) Cerebrovascular and cerebral effects of nimodipine — an update. Acta Neurochir [Suppl 45]: 11–20
Scriabine A, Schuurman T, Traber J (1989) Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB 3: 1799–1806
Gerber MC, Tejwani GA, Gerber N, Bianchine JR (1985) Drug interactions with cimetidine: an update. Pharmacol Ther 27: 353–370
Kirch W, Ohnhaus EE (1987) Neuere Aspekte zu Arzneimittelwechselwirkungen mit den H2-Antagonisten Cimetidin und Ranitidin. Med Klin 82: 400–404
Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12: 321–366
Mitchard M, Harris A, Mullinger BM (1987) Ranitidine drug interactions — a literature review. Pharmacol Ther 32: 293–325
Kirch W, Janisch HD, Heidemann H, Rämsch KD, Ohnhaus EE (1983) Einfluß von Cimetidin und Ranitidin auf Pharmakokinetik und antihypertensiven Effekt von Nifedipin. Dtsch Med Wochenschr 108: 1757–1761
Kirch W, Hutt HJ, Heidemann H, Rämsch KD, Janisch HD, Ohnhaus EE (1984) Drug interactions with nitrendipine. J Cardiovasc Pharmacol 6 [Suppl 7]: S982-S985
Janzon K, Edgar B, Lundborg P, Regardh CG (1986) The influence of cimetidine and spironolactone on the pharmacokinetics and haemodynamic effects of felodipine in healthy subjects. Acta Pharmacol Toxicol 59 [Suppl 5]: 98, Abstract No. 258
Dylewics P, Kirch W, Ohnhaus EE (1987) Wechselwirkungen von Nifedipin mit Ranitidin und Cimetidin. Therapiewoche 37: 4837–4842
Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR (1987) Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol 23: 311–315
Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ (1988) Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 43: 673–680
Wingender W, Rämsch KD, Proeve J, Kuhlmann J (1989) Influence of cimetidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol 36 (suppl): A 265, Abstract No. PP 11.30
Halabi A, Kirch W, Nahoui R (1990) Influence of ranitidine on kinetics of nitrendipine and on noninvasive hemodynamic parameters. Ther Drug Monit 12: 303–304
Van Harten J, van Brummelen P, Lodewijks MThM, Meindert D, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 43: 332–341
Rämsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol 6 [Suppl 1]: 73–80
Fleitman J, Torosian G, Perrin JH (1982) Improved high-performance liquid chromatographic assay for cimetidine using ranitidine as an internal standard. J Chromatogr 229: 255–258
Mihaly GW, Drummer OH, Marshall A, Smallwood LA, Louis WJ (1980) High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine. J Pharm Sci 69: 1155–1157
Nazario M (1986) The hepatic and renal mechanisms of drug interactions with cimetidine. Drug Intell Clin Pharm 20: 342–348
Smith SR, Kendall MJ (1988) Ranitidine versus Cimetidine — a comparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 15: 44–56
Rowland M, Tozer TN (1989) Clinical Pharmacokinetics: Concepts and Applications. 2nd edit. Lea and Febiger, Philadelphia
Somogyi A, Gugler R (1983) Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8: 463–495
Grant SM, Langtry HD, Brogden RN (1989) Ranitidine — an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37: 801–870
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mück, W., Wingender, W., Seiberling, M. et al. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol 42, 325–328 (1992). https://doi.org/10.1007/BF00266356
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00266356